Peter Rieckmann

18.8k total citations · 2 hit papers
266 papers, 13.1k citations indexed

About

Peter Rieckmann is a scholar working on Pathology and Forensic Medicine, Immunology and Neurology. According to data from OpenAlex, Peter Rieckmann has authored 266 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Pathology and Forensic Medicine, 63 papers in Immunology and 52 papers in Neurology. Recurrent topics in Peter Rieckmann's work include Multiple Sclerosis Research Studies (145 papers), Peripheral Neuropathies and Disorders (35 papers) and Rheumatoid Arthritis Research and Therapies (26 papers). Peter Rieckmann is often cited by papers focused on Multiple Sclerosis Research Studies (145 papers), Peripheral Neuropathies and Disorders (35 papers) and Rheumatoid Arthritis Research and Therapies (26 papers). Peter Rieckmann collaborates with scholars based in Germany, United States and Canada. Peter Rieckmann's co-authors include Klaus V. Toyka, Helen Tremlett, John H. Kehrl, Per Soelberg Sørensen, Gavin Giovannoni, Patrick Vermersch, Gıancarlo Comı, S. Poser, Kottil Rammohan and Peter Flachenecker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Peter Rieckmann

261 papers receiving 12.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

2010 689 citations Gavin Giovannoni, Gıancarlo Comı et al. profile →
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters

2002 505 citations Peter Flachenecker, Boris Kallmann et al. Multiple Sclerosis Journal profile →

Peers

Countries citing papers authored by Peter Rieckmann

Since Specialization

Citations

This map shows the geographic impact of Peter Rieckmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Rieckmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Rieckmann more than expected).

Fields of papers citing papers by Peter Rieckmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Rieckmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Rieckmann. The network helps show where Peter Rieckmann may publish in the future.

Co-authorship network of co-authors of Peter Rieckmann

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Rieckmann. A scholar is included among the top collaborators of Peter Rieckmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Rieckmann. Peter Rieckmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 2022 ·Expert Opinion on Pharmacotherapy ·Sven G. Meuth, Antonios Bayas, Boris Kallmann, Ralf A. Linker, Peter Rieckmann, Mike P. Wattjes, Mathias Mäurer, Christoph Kleinschnitz	21
2	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice 2021 ·Therapeutic Advances in Neurological Disorders ·Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja‐Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, (unknown), Bassem Yamout	11
3	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies 2021 ·Advances in Therapy ·Gavin Giovannoni, Gıancarlo Comı, Kottil Rammohan, Peter Rieckmann, Fernando Dangond, Birgit Keller, Dominic Jack, Patrick Vermersch	23
4	Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart® 2018 ·Advances in Therapy ·Peter Rieckmann, Matthias Schwab, Dieter Pöhlau, Iris‐Katharina Penner, (unknown), (unknown), Antonios Bayas	12
5	Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study 2017 ·Multiple Sclerosis Journal ·Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Gıancarlo Comı, Fernando Dangond, Abidemi Adeniji, Patrick Vermersch	243
6	Electrophysiological assessment of nociception in patients with Parkinson's disease: A multi-methods approach 2016 ·Journal of the Neurological Sciences ·Janosch A. Priebe, Miriam Kunz, (unknown), Peter Rieckmann, Stefan Lautenbacher	11
7	Late-onset myasthenia gravis – CTLA4low genotype association and low-for-age thymic output of naïve T cells 2014 ·Journal of Autoimmunity ·Wen‐Yu Chuang, Philipp Ströbel, (unknown), Peter Rieckmann, Wilfred A. Nix, Berthold Schalke, Ralf Gold, Andreas Opitz, Erdwine Klinker, Masayoshi Inoue, Hans Konrad Müller‐Hermelink, Güher Saruhan‐Direskeneli, Peter Bugert, Nick Willcox, Alexander Marx	18
8	Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study 2011 ·UCL Discovery (University College London) ·Patrick Vermersch, Giacomo P. Comi, (unknown), Gavin Giovannoni, (unknown), Peter Rieckmann, Per Soelberg Sørensen, (unknown), (unknown), Peter Chang, Orestis Papasouliotis, Stan S. Greenberg	1
9	Targeting Progressive Neuroaxonal Injury 2011 ·CNS Drugs ·Amit Bar‐Or, Peter Rieckmann, Anthony Traboulsee, V. Wee Yong	16
10	Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS 2010 ·Neurology ·Elaine Kingwell, Marcus Koch, Benjamin S. Leung, S. Isserow, John Geddes, Peter Rieckmann, Helen Tremlett	75
11	EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units 2010 ·European Journal of Human Genetics ·Tony Kam-Thong, Darina Czamara, Koji Tsuda, Karsten Borgwardt, Cathryn M. Lewis, Angelika Erhardt, Bernhard Hemmer, Peter Rieckmann, (unknown), Frank Weber, Christiane Wolf, Andreas Ziegler, Benno Pütz, (unknown), Bernhard Schölkopf, Bertram Müller‐Myhsok	67
12	Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study 2009 ·UCL Discovery (University College London) ·Peter Rieckmann, G. Comi, Sandra Cook, Gavin Giovannoni, (unknown), Per Soelberg Sørensen, Patrick Vermersch, Pen-Heng Chang, Anthony Hamlett, (unknown), Bruno Musch, Stan S. Greenberg	9
13	Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose 2007 ·Der Nervenarzt ·Ralf Gold, Peter Rieckmann	2
14	Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26) 2006 ·BMC Cancer ·Dirk Vordermark, Klemens Ruprecht, Peter Rieckmann, Wolfgang Roggendorf, Giles H. Vince, Monika Warmuth‐Metz, Oliver Kölbl, Michael Flentje	36
15	CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation 2002 ·Nature Medicine ·Ralf A. Linker, Mathias Mäurer, Stefanie Gaupp, Rudolf Martini, Bettina Holtmann, Ralf Giess, Peter Rieckmann, Hans Lassmann, Klaus V. Toyka, Michael Sendtner, Ralf Gold	325
16	Comment on the contribution by F. Zipp and K. P. Wandinger. Current recommendations for vaccinations in multiple sclerosis 2001 ·Der Nervenarzt ·Peter Rieckmann, (unknown), Peter Flachenecker, Klaus V. Toyka	1
17	Multiple sclerosis: more than inflammation and demyelination 2001 ·Trends in Neurosciences ·Peter Rieckmann, Kenneth J. Smith	23
18	Differential Expression of Sense and Antisense Transcripts of the Mitochondrial DNA Region Coding for ATPase 6 in Fetal and Adult Porcine Brain: Identification of Novel Unusually Assembled Mitochondrial RNAs 2000 ·Biochemical and Biophysical Research Communications ·Uwe Michel, (unknown), Roland Nau, Peter Rieckmann	12
19	Fasciculations: Clinical, electromyographic, and ultrasonographic assessment 1996 ·Journal of Neurology ·Carl D. Reimers, Ulf Ziemann, Alexander Scheel, Peter Rieckmann	50
20	Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1. 1991 ·The Journal of Experimental Medicine ·Peter Rieckmann, Guido Poli, John H. Kehrl, A S Fauci	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact